COMMUNIQUÉS West-GlobeNewswire

Pacira BioSciences Reports Second Quarter 2025 Financial Results
05/08/2025
-- Solid execution across corporate, clinical and commercial initiatives -- -- Several key milestones advance 5x30 path to growth -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Aug. 05, 2025 (GLOBE [...]
IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call
05/08/2025
Investors are reminded that Shareholders of record as of August 7, 2025, will receive a 15% stock dividend payment LAWRENCEVILLE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN) , a clinical-stage [...]
Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
05/08/2025
NEWTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic [...]
Jushi Holdings Inc. Reports Second Quarter 2025 Financial Results
05/08/2025
Revenue of $65.0 million , Reflecting Year-over-Year and Sequential Growth Net Loss of $12.3 million, Compared to $17.0 million in the First Quarter of 2025 Adjusted EBITDA Increased 39.6% Quarter-over-Quarter to $13.7 [...]
Day One Reports Second Quarter 2025 Financial Results and Corporate Progress
05/08/2025
OJEMDA™ (tovorafenib) net product revenue of $33.6 million in Q2 2025, a 10% quarter-over-quarter increase OJEMDA full-year 2025 net product revenue expected to be $140 to $150 million Ended the second quarter with $453 [...]
Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne
05/08/2025
M dxh ealth Reports Preliminary Second Quarter 202 5 Results , Reaches Positive Adjusted EBITDA , and A nnounces Acquisition of Exo some D iagnostics B usiness from Bio - Techne Year-over-year Q 2 revenues increased by [...]
Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025
05/08/2025
Company to host conference call to discuss financial results and provide a corporate update on August 12, 2025 at 4:30 p.m. ET SCOTTSDALE, Ariz., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey [...]
Elegantly Healthy Announces New Book “Being Healthy,” Plus Companion Livestream Series and Online Course
05/08/2025
Los Angeles, CA , Aug. 05, 2025 (GLOBE NEWSWIRE) -- Elegantly Healthy , a wellness and lifestyle brand dedicated to mindful living and natural healing, today announced the release of a new book titled Being Healthy , [...]
Channel Medsystems Appoints Nelson Whistance as CEO to Lead Next Phase of Growth
05/08/2025
BERKELEY, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Channel Medsystems, the medical device company that successfully launched the innovative Cerene ® technology for endometrial cryotherapy, announced today the [...]
Soda Health Expands Retail and Pharmacy Network: &more Card Now Accepted at Publix Locations Across the Southeast
05/08/2025
BENTONVILLE, Ark., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Soda Health, a technology company reinventing benefits administration, today announced that its &more benefit cards are now accepted at Publix locations across [...]
Press release: CMS Approves Additional Payment for Sequana Medical’s alfapump® system in Hospital Inpatient Cases
05/08/2025
CMS Approves Additional Payment for Sequana Medical’s alfapump® system in Hospital Inpatient Cases alfapump® New Technology Add-on Payment (NTAP) Included in CMS Final Fiscal Year 2026 Rule and in effect by October 1, [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 31 - 2025
05/08/2025
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 28 juillet au 01 août 2025 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2025
05/08/2025
Aggregated presentation by day and by market Statement of transactions in own shares from July 28th to August 1 st 2025 Name of the issuer Identity code of the issuer (Legal Entity Identifier) Day of the transaction [...]
VALNEVA Déclaration d’actions et de droits de vote : 31 juillet 2025
05/08/2025
VALNEVA Déclaration d’actions et de droits de vote 31 juillet 2025 __________________________________________________________________________________________ Dénomination sociale : VALNEVA Adresse du siège social : 6 [...]
VALNEVA Declaration of shares and voting rights: July 31, 2025
05/08/2025
VALNEVA Declaration of shares and voting rights July 31, 2025 __________________________________________________________________________________________ Company name: VALNEVA Registered office: 6 rue Alain Bombard, [...]
Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
05/08/2025
Phase 1/2 dose expansion data for Nectin-4 targeting ADC CRB-701 to be presented at ESMO 2025 Initiated 7-day MAD portion of Phase 1 study for obesity drug CRB-913 All three clinical programs (CRB-701, CRB-913, CRB-601 [...]
electroCore Appoints James C. Theofilos to the Board of Directors
05/08/2025
ROCKAWAY, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that James C. Theofilos has been appointed to the Board [...]
Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
05/08/2025
RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc . (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases ( [...]
ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025
05/08/2025
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies [...]

Pages